Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
liver toxicity
Biotech
Analysts unshaken by patient death in BMS lung fibrosis trial
Analysts were quick to dismiss concerns that the liver toxicity seen with BMS' admilparant spell larger trouble for the LPA1 drug class.
Darren Incorvaia
Oct 1, 2026 10:22am
UniQure halts mid- to high-dosing for AAV gene therapy
Feb 6, 2026 10:56am
FDA puts Intellia CRISPR trials on hold over raised liver enzyme
Oct 30, 2025 6:37am
Intellia pauses phase 3 CRISPR trials after patient hospitalized
Oct 27, 2025 9:45am
FDA lifts diabetes hold after Biomea mitigates liver tox risk
Sep 27, 2024 7:10am
Tango drops USP1 inhibitor over liver toxicity in phase 1 trial
May 23, 2024 8:11am
